ConductScience.org, home

Comparison · NCT01807871-deaths

Nicotine Patch, Experimental Use vs Nicotine Patch, Labeled Use: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Nicotine Patch, Experimental Use vs Nicotine Patch, Labeled Use: deaths from any cause. Trial comparisons, record NCT01807871-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01807871-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.002810.0004960.0157wilson
Risk in group 20.00290.0005120.0162wilson
Risk difference, group 1 minus group 2-0.0000896-0.01360.0131newcombe hybrid score
Risk ratio, group 1 over group 20.9690.060915.4log
Odds ratio, group 1 over group 20.9690.060415.6log
Number needed to treat, for one fewer death from any cause on Nicotine Patch, Experimental Use than on Nicotine Patch, Labeled Use11,200from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Nicotine Patch, Experimental Use
Participants will continue to use nicotine patch after they lapse and resume smoking as long as smoking is less than 75% of pre study levels.~nicotine patch, experimental use: nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
1356EG000
Group 2Nicotine Patch, Labeled Use
Participants will discontinue using the nicotine patch when they resume smoking. This is the current FDA approved use of the nicotine patches.~nicotine patch, labeled use: nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
1345EG001

Harm

What it counts
Total, all-cause mortality
Time frame
12 weeks

Source ClinicalTrials.gov

Trial

Title
Treatment of Smoking Lapses and Relapses
NCT number
NCT01807871
Phases
PHASE4
Conditions
Smoking Cessation
Interventions
nicotine patch, experimental use, nicotine patch, labeled use
Lead sponsor
University of Vermont
Results first posted
2017-03-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01807871-deaths